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and only a small number has been reported to occur in the head and neck. Although the major-
ity of myoepithelial tumours of the soft tissue are benign, some can be aggressive and develop
distant metastases.
We describe a patient with malignant myoepithelial tumour occurring in the soft tissue of
the head and neck and rapid metastatic progression. In contrast to previous publications warn-
ing for overtreatment of patients with myoepithelial tumours, our report suggests that early
and correct diagnosis followed by a radical therapeutic approach is required when there is evi-
dence of malignancy.c 2006 Elsevier Ltd. All rights reserved.
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dCase report
A 17-year-old boy presented with a large, slowly growing,
unilateral neck mass (Fig. 1). This painless tumour had
developed over a period of two years, with a recent accel-
eration in growth following an upper respiratory tract infec-741-9409/$ - see front matter c 2006 Elsevier Ltd. All rights reserved
oi:10.1016/j.ooe.2006.09.001
* Corresponding author. Tel.: +32 2 764 1976; fax: +32 2 764 8935.
E-mail address: hamoir@orlo.ucl.ac.be (M. Hamoir).tion. No other symptoms were associated and he was in
good overall health.
The rest of the clinical examination was normal. Mag-
netic resonance imaging showed a 15 cm polycyclic mass,
hyperintense in T2-weighted sequence and hypointense in
T1-weighted sequence (Fig. 2). The tumour was well
circumscribed, without infiltration of the adjacent sterno-
cleidomastoid or posterolateral muscles. PET-scan-imaging
confirmed the presence of a voluminous hypermetabolic.
Figure 2 T2-weighed nuclear magnetic resonance imaging
reveals a hyperintense tumour.
Figure 3 Macroscopic view after resection showing a yellow-
ish, hard, nodular tumour (5 · 5 · 5.5 cm).Figure 1 Clinical presentation of the tumour mass in the left
posterolateral neck triangle.
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open biopsy performed in another hospital, the patient
was referred to our institution with the presumed patholog-
ical diagnosis of a malignant tumour arising in the soft tis-
sue. After multidisciplinary discussion, the patient
underwent a wide tumour resection including an extended
radical neck dissection, resecting paraspinal muscles
(Fig. 3).
Histopathological examination of the resected specimen
showed a poorly differentiated malignant neoplasm with a
somewhat pleomorphic epithelioid and round cell
morphology.
In some areas, the tumour cells were arranged in nests
and had small amounts of eosinophilic or clear cytoplasm
(Fig. 4A and B). Mitotic count was as high as 25 mitoses
per 10 hpf and Ki67 (1/100, clone MIB-1, Dako, Glostrup,
Denmark) immunostaining showed a tumor-proliferating in-
dex of 50%. Tumour cells showed multifocal positivity forcytokeratin 22 (1/400, cytokeratin cocktail 40–68 kD, Bio-
media, Foster City, USA) (Fig. 4C), S-100 protein (1/2000,
rabbit polyclonal, Dako, Glostrup, Denmark), and Epithelial
Membrane Antigen (EMA, 1/200, clone E29, Dako, Glostrup,
Denmark), as well as for Vimentin (1/50, clone V9, Dako,
Glostrup, Denmark) (Fig. 5A–C). Tumour cells were also po-
sitive for alpha gamma actin (1/100, clone HHF35, Dako,
Carpinteria, USA), CD10 (1/50, clone 56C6, Biocare Medical,
Walnut Creek, USA) and focally for h-caldesmon (1/30,
clone h-CALD, Neomarkers, Fremont, USA) (Fig. 6A–C).
These stainings prove the myogenous component. Only a
few cells stained with Glial Fibrillary Acidic Protein (GFAP,
1/2000, rabbit polyclonal, Dako, Glastrup, Denmark)
(Fig. 5D), while staining with desmin (1/500, clone D33,
Dako, Glostrup, Denmark) and p63 (1/500, clone
4A4+Y4A3, Neomarkers, Fremont, USA) were negative. The
appearance and immunophenotype fitted very well with a
myoepithelial carcinoma, apparently arising in the soft tis-
sue. Additionally, in the neck dissection specimen, 17/22
resected lymph nodes were found invaded and four of them
showed extracapsulary spread.
Six weeks after surgery the patient was treated by adju-
vant postoperative radiotherapy (70 Gy, 5 weeks, 2 Gy/
day). Unfortunately, six months after initial surgery, multi-
ple bone, lung and pleural metastases were diagnosed, lead-
ing to palliative chemotherapy: Cisplatin 110 mg/m2 (day 1)
and 5 Fluorouracil 1000 mg/m2/day (days 1–4) every three
weeks. Nevertheless, the disease progressed rapidly. There-
fore a second line chemotherapy regimen was adminis-
trated: Paclitaxel 175 mg/m2 (day 1) and gemcitabine
1000 mg/m2(days 1 and 8), every three weeks. Despite
these aggressive treatment modalities, the patient’s gen-
eral condition deteriorated and he died 10 months after ini-
tial treatment.Discussion
The most common location of myoepitheliomas is the sal-
ivary gland, where they account for 1.5% of tumours.1 In
addition myoepitheliomas have been found to occur also
Figure 4 (A) A low magnification overview of the tumour centered on a necrotic area (white arrows) and showing an alternance of
fibrous bands and epithelioid structures (H and E). (B) Higher magnification displaying cordonal areas made of loosely cohesive
tumour cells characterized by a moderately abundant cytoplasm with a sometimes-clear appearance and pleiomorphic nuclei (H and
E). (C) CK22 immunohistochemical expression of tumour cells confirming their epithelial nature.
Figure 5 Immunostaining with EMA (A), Vimentin (B), S-100 protein (C) and GFAP (D).
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breast7 and lung.8 The separate entity of myoepithelial
tumour arising primarily in the soft tissue was recognized
for the first time 10 years ago.2–9 The broad morpholog-
ical spectrum of myoepithelial tumours probably is themean reason why they were not easily recognized
before.
Only 15% of all these soft tissue myoepitheliomas occur
in the head and neck region.3 The great majority is found
in the limbs and limb girdles. Although myoepitheliomas
Figure 6 Positive immunostaining with alpha gamma actin (A), h-caldesmon (B) and CD10 (C) demonstrates the myogenous
character of the tumour.
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tissue, less than 30% occur in the deep soft tissue.3
Extraglandular myoepithelioma is a very rare tumour. Un-
til Hornick and Fletcher recently published a series of 101
cases, gathered from medical centers all over the world,
fewer than 40 cases of soft tissue myoepithelial tumours
had been reported.3 The World Health Organisation defines
myoepthelioma as a rare tumour composed of myoepithelial
cells which have a solid, myxoid and reticular growth
pattern. Characteristic for these tumours are spindle,
plasmacytoid, epithelioid, and clear cells, which have elec-
tron-microscopic and immunohistochemical features of
myoepithelial differentiation. An almost total absence of
ductal epithelial structures is required.10 Only 20% of the soft
tissuemyoepithelial tumours show ductal differentiation and
can therefore been classified as mixed tumours (‘‘pleomor-
phic adenomas’’).3 There is a consensus that myoepithelio-
mas and mixed tumours fall along a continuum of tumours
with overlapping histological appearances and similar clini-
cal behaviour. Nevertheless, distinguishing between these
two tumours stays important because myoepitheliomas be-
have more aggressively than pleomorphic adenomas.10
The differential diagnosis should include pleomorphic
adenoma, myxoid chondrosarcoma, chondroid syringoma,
parachordoma, myxoid liposarcoma, and ossifying fibromyx-
oid tumour of soft parts, synovial sarcoma, epithelioid sar-
coma and metastatic carcinoma.10
Clinically, most head and neck myoepithelial soft tissue
tumours present as painless or painful neck mass. This neo-
plasm seems to have an equal gender distribution, and is
usually diagnosed in the third to fifth decade.3 Macroscopi-
cally, the tumour is well circumscribed with in many cases anodular or lobulated aspect. Histological diagnosis of soft
tissue myoepitheliomas, requires similar criteria as those
established for their salivary gland counterparts. Approxi-
mately 40% of all myoepithelial tumours of the soft tissue
are found malignant at time of diagnosis.3
Most tumours show a mixed solid and reticular or trabec-
ular architecture and are composed of epithelioid, plasma-
cytoid, spindled and/or clear cells in a variable myxoid or
hyalinized stroma.3 Tumour cells can be, as stated above,
epithelioid (round or polygonal cells with variable abundant
eosinophilic cytoplasma) spindled (short or elongated cells
with eosinophilic to clear cytoplasma and thin, somewhat
tapered nuclei) plasmocytoid (plump cells with abundant,
eccentric hyaline cytoplasmic inclusions) or clear (clear
cytoplasma with small nuclei) or vacuolates (lipoblast-
like).3–10
Hornick and Fletcher found that soft tissue myoepithelial
tumours showed positivity for cytokeratin and/or EMA.3 The
vast majority (93%) of the tumours was positive for keratin,
most often AE1/AE3 or pan-keratin (PAN-K), and in a lesser
degree for CAM5.2 and for CK 14. Positivity for EMA was
seen in 63% of the tumours. Nearly all soft tissue myoepithe-
lial tumours were positive for S-100 protein (87%).3 Approx-
imately in half of the cases an immunoreactivity for GFAP
was present.3 The myoepithelial tumour cells often ex-
pressed myogenic markers, the most sensitive being calpo-
nin (86%). Smooth muscle antigen (SMA) and desmin
stained only a small percentage of the tumours.3 Expression
of p63 was only detected in a minority (25%) of all cases,
providing supportive diagnostic evidence.3
Myoepithelial tumours with no to mild cytologic atypia
(low-grade) can be classified as myoepithelioma, whereas
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classified as myoepithelial carcinoma (vesicular or coarse
chromatin, prominent, often large nucleoli, or nuclear
pleomorphism).3
High-grade cytologic atypia in myoepithelial tumour is a
clear indication of malignancy. But the diagnosis of malig-
nancy is much more difficult if there is a lack of cytologic
atypia, since cytologic atypia are not required for the diag-
nosis of myoepithelial carcinoma.11 When located in salivary
glands, a part from cytologic atypia, mitotic rate and tu-
mour infiltrating in surrounding salivary gland or other nor-
mal tissues can be helpful in differentiating between benign
and malignant myoepitheliomas.11–14 However, in soft tis-
sues, an infiltrative growth pattern is insufficient to assert
a diagnosis of myoepithelial carcinoma. In the Hornick and
Fletcher series, margin invasion was not associated with
recurrence or metastasis. These authors showed that there
was a statistically significant difference in recurrence rate
(p = 0.04) and frequency of metastasis (p < 0.001) between
the tumours classified histologically as benign and malig-
nant. In the benign or low-grade cytology group 18% had lo-
cal recurrence and none metastasised when 42% had local
recurrence and 32% metastatic disease. in the cytologically
malignant group.3 So, it seems that the presence of even
moderate cytologic atypia (prominent nucleoli, vesicular
or coarse chromatin, pleomorphism) in soft tissue myoepi-
thelioma should be regarded as myoepithelial carcinoma.3
Complete excision with clear margins is the treatment of
choice. Postoperative radiotherapy is recommended in case
of close margins and/or lymph node metastasis.10 In the
presence of distant metastases, the prognosis is dismal.
Conclusion
Extraglandular myoepithelial carcinoma seldom occurs in
the soft tissue of the head and neck. Myoepithelial carci-
noma was only recently recognized to occur primarily in soft
tissue, and, so far, only a small number has been reported
to occur in the head and neck. Our case suggests that some-
times this disease can have an aggressive behaviour with ra-
pid apparition of distant metastases. Because this tumour
can have cells with different morphologic features and dif-
ferent histological patterns, immunohistochemical analysis
is essential for an irrefutable diagnosis.
In contrast to what was stated in earlier publications,
which warned for overtreatment of patients with myoepi-
thelial tumours, a rapid and correct diagnosis followed by
an aggressive treatment, when there is evidence of malig-
nancy, is advised. Incorrect diagnosis and ignorance about
this potentially aggressive disease can lead to under
treatment.Acknowledgement
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